Dirk Fischer is leading the neuromuscular research group at the University Childrens Hospital in Basel, Switzerland. 

One of  his main research interests is to identify objective clinical endpoints or surrogate imaging markers that are useful in evaluating disease progression in muscular dystrophies and related neuromuscular disorders. 

The second and most important area of scientific interest includes clinical studies aimed to slow the muscle degeneration in patients with muscular dystrophies.  A positive effect on muscle metabolism of a treatment with metformin and L-citrulline was found in a monocenter randomised placebo controlled trial in 47 ambulant patients with Duchenne muscular dystrophy.

Currently, his group is leading an international multicentre randomised placebo controlled trial in 47 ambulant patients with Duchenne muscular dystrophy assessing the efficacy and safety of tamoxifen.